In our evaluation of whether the activation of ADRB2 signaling by terbutaline (TERB), an ADRB2 agonist, was involved in NSCLC resistance to apatinib therapy, terbutaline increased the IC50 of apatinib – 26.62 μM vs. 20.21 μM in H522 cells and 12.98 μM vs. 10.31 μM in H460 cells compared to the vehicle group (Fig. 2A). Here, ADRB2 is linked to non-small cell lung carcinoma.